Abstract PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules
consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to …

Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …

PROTACs (proteolysis targeting chimeras) are an emerging class of promising therapeutic
modalities that degrade intracellular protein targets by hijacking the cellular ubiquitin …

Covering: upto 2022 Natural products have an embedded recognition of protein surfaces.
They possess this property as they are produced by biosynthetic enzymes and are …

Targeted protein degradation by small-molecule degraders represents an emerging mode of
action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules …

Targeted protein degradation technology has evolved a brand-new therapeutic modality
from an innovative drug discovery perspective. Though the classical PROTACs has …

Proteolysis targeting chimera (PROTAC) is one of the most frequently used technologies for
targeted protein degradation. PROTACs are composed of target protein ligand, E3 ligase …

Currently, a new technology termed PROTAC, proteolysis targeting chimera, has been
developed for inducing the protein degradation by a targeting molecule. This technology …

Abstract Targeted Protein Modification (TPM) is an umbrella term encompassing numerous
tools and approaches that use bifunctional agents to induce a desired modification over the …

Proteolysis-targeting chimeras (PROTACs) is a fast-growing technology providing many
strengths over inhibition of protein activity directly and is attracting increasing interest in new …